Accordingly, several ongoing, prevention clinical trials describe APOE ε4 as an inclusion factor (NCT02565511, NCT03131453, NCT02569398) and large-scale screening programs are being established to identify APOE ε4 carriers for AD preventive clinical trials32. This evidence concerns the gene APOE and Alzheimer disease.